Table 1

Treatment	Uveitis, n	Patients exposed	Rate	OR (CI)	p	Exposure years	Rate/1000 years (CI)	HR (CI)	p

MTX	25	1403	0.018	comparator	–	3459	7.2 (4.9–10.7)	comparator	–
ETA mono	17	475	0.036	2.1 (1.1–3.8)	0.022	1031	16.5 (10.3–26.5)	2.2 (1.2–4.1)	0.012
ETA+MTX	20	1225	0.016	0.9 (0.5–1.7)	0.769	3309	6.0 (3.9–9.4)	0.9 (0.5–1.6)	0.763
ADA mono	7	148	0.047	2.7 (1.2–6.4)	0.016	189	37.0 (17.7–77.7)	3.9 (1.7–9.1)	0.002
ADA+MTX	6	216	0.028	1.6 (0.6–3.9)	0.320	294	20.4 (9.2–45.4)	2.3 (0.9–5.6)	0.072

Steroids +	21	1174	0.018	0.8 (0.5–1.3)	0.278	2886	7.3 (4.7–11.2)	0.7 (0.4–1.2)	0.214
Steroids −	54	2293	0.024			5395	10.0 (7.7–13.1)
MTX +	51	2844	0.018	0.5 (0.3–0.8)	0.001	7062	7.2 (5.5–9.5)	0.4 (25–0.65)	0.0002
MTX −	24	623	0.039			1220	19.7 (13.2–29.4)
ETA +	37	1700	0.022	1.01 (0.6–1.6)	0.958	4340	8.5 (6.2–11.8)	0.98 (0.6–1.5)	0.935
ETA −	38	1767	0.022			3941	9.6 (7.0–13.3)
ADA +	13	364	0.036	1.8 (0.99–3.3)	0.051	483	26.9 (15.6–46.4)	2.7 (1.5–4.9)	0.002
ADA −	62	3103	0.020			7798	8.0 (6.2–10.2)